Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

167 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Long-term remission of refractory Rosai-Dorfman disease after salvage therapy with clofarabine in an adult patient.
Hinterleitner C, Steurer M, Dörfel D, Heitmann J, Kreisselmeier KP, Müller K, Kopp HG, Wirths S, Haap M, de Fend LQ, Horger M, Rodriguez-Galindo C, Kanz L, Müller MR. Hinterleitner C, et al. Among authors: heitmann j. Ann Hematol. 2019 Jan;98(1):227-230. doi: 10.1007/s00277-018-3421-7. Epub 2018 Jul 6. Ann Hematol. 2019. PMID: 29980874 No abstract available.
Increased soluble HLA in COVID-19 present a disease-related, diverse immunopeptidome associated with T cell immunity.
Nelde A, Rieth J, Roerden M, Dubbelaar ML, Hoenisch Gravel N, Bauer J, Klein R, Hoheisel T, Mahrhofer H, Göpel S, Bitzer M, Hörber S, Peter A, Heitmann JS, Walz JS. Nelde A, et al. Among authors: heitmann js. iScience. 2022 Dec 22;25(12):105643. doi: 10.1016/j.isci.2022.105643. Epub 2022 Nov 19. iScience. 2022. PMID: 36439376 Free PMC article.
Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency.
Heitmann JS, Tandler C, Marconato M, Nelde A, Habibzada T, Rittig SM, Tegeler CM, Maringer Y, Jaeger SU, Denk M, Richter M, Oezbek MT, Wiesmüller KH, Bauer J, Rieth J, Wacker M, Schroeder SM, Hoenisch Gravel N, Scheid J, Märklin M, Henrich A, Klimovich B, Clar KL, Lutz M, Holzmayer S, Hörber S, Peter A, Meisner C, Fischer I, Löffler MW, Peuker CA, Habringer S, Goetze TO, Jäger E, Rammensee HG, Salih HR, Walz JS. Heitmann JS, et al. Nat Commun. 2023 Aug 18;14(1):5032. doi: 10.1038/s41467-023-40758-0. Nat Commun. 2023. PMID: 37596280 Free PMC article. Clinical Trial.
AML-VAC-XS15-01: protocol of a first-in-human clinical trial to evaluate the safety, tolerability and preliminary efficacy of a multi-peptide vaccine based on leukemia stem cell antigens in acute myeloid leukemia patients.
Jung S, Nelde A, Maringer Y, Denk M, Zieschang L, Kammer C, Özbek M, Martus P, Hackenbruch C, Englisch A, Heitmann JS, Salih HR, Walz JS. Jung S, et al. Among authors: heitmann js. Front Oncol. 2024 Oct 14;14:1458449. doi: 10.3389/fonc.2024.1458449. eCollection 2024. Front Oncol. 2024. PMID: 39469638 Free PMC article.
NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia.
Märklin M, Heitmann JS, Fuchs AR, Truckenmüller FM, Gutknecht M, Bugl S, Saur SJ, Lazarus J, Kohlhofer U, Quintanilla-Martinez L, Rammensee HG, Salih HR, Kopp HG, Haap M, Kirschniak A, Kanz L, Rao A, Wirths S, Müller MR. Märklin M, et al. Among authors: heitmann js. Nat Commun. 2017 Oct 2;8(1):755. doi: 10.1038/s41467-017-00830-y. Nat Commun. 2017. PMID: 28970470 Free PMC article.
167 results